<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02492100</url>
  </required_header>
  <id_info>
    <org_study_id>15-158</org_study_id>
    <nct_id>NCT02492100</nct_id>
  </id_info>
  <brief_title>A Multimodal Intervention to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant Survivors</brief_title>
  <official_title>A Multimodal Intervention to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is evaluating the feasibility and impact of an intervention to improve
      sexual function in stem cell transplant survivors on participants' sexual function, quality
      of life, and mood.

      - It is expected that about 50 stem cell transplant survivors will take part in this research
      study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Frequently survivors of stem cell transplantation report significant problems with their
      sexual function that impacts their quality of life, mood, and their intimacy and relationship
      with their partners. These issues can be very distressing to patients and their loved ones.
      The study doctors want to know if the introduction of an intervention focused on improving
      sexual function may improve a participant's overall care and quality of life.

      The intervention includes a comprehensive assessment by a transplant clinician who is trained
      in sexual dysfunction assessment to explore the reasons for sexual dysfunction and focus on
      ways to improve the participant's symptoms. The study will use a series of questionnaires to
      measure a participant's sexual function, quality of life, and mood.

      The main purpose of this study is examine whether this intervention is feasible and helpful
      for participants in terms of improving their symptoms and overall quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility Primary Endpoint</measure>
    <time_frame>6 months</time_frame>
    <description>intervention deemed feasible if at least 75% of patients screening positive for sexual dysfunction causing distress agree to participate and at least 80% complete at least one additional follow-up visit. This is not a composite outcome. Study is deemed feasible (yes) if both criteria are met.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Sexual Function: Promis Sexual Function and Satisfaction Measure</measure>
    <time_frame>Baseline to 6 Months</time_frame>
    <description>Interest in sex at 6 months, raw score range 2-20 with higher scores indicating higher interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life: Functional Assessment of Cancer Therapy- Bone Marrow Transplant</measure>
    <time_frame>Baseline to 6 Months</time_frame>
    <description>quality of life at 6 months compared to baseline using the Functional Assessment of Cancer Therapy - Bone Marrow Transplant. Score range 0-164 with higher score indicating better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Psychological Distress Scores - Hospital and Anxiety Depression Scale and Patient Health Questionnaire-9</measure>
    <time_frame>Baseline to 6 Months</time_frame>
    <description>change in HADS depression score, depression subscale of the HADS has a score range of 0-21, with higher scores indicating more depression symptoms.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Sexual Dysfunction</condition>
  <arm_group>
    <arm_group_label>Multi-modality sexual dysfunction intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- Patients in remission &gt; 6 months after allogeneic bone marrow transplant
Patient Enrollment and Baseline Data Collection
First Intervention Visit:
Comprehensive assessment of sexual dysfunction
Normalization &amp; Education
Therapeutic interventions
Referral to Sexual Health Clinic if applicable
Follow-Up Intervention Visit --- Referral to Sexual Health Clinic if applicable</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Multi-modality sexual dysfunction intervention</intervention_name>
    <arm_group_label>Multi-modality sexual dysfunction intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (â‰¥18 years) with hematologic malignancy who underwent an allogeneic HCT
             at least 6 months prior to study enrollment.

          -  Ability to speak English or able to complete questionnaires with assistance required
             from an interpreter or family member.

          -  Positive screen for sexual dysfunction that is causing distress based on the National
             Comprehensive Cancer Network survivorship guidelines

        Exclusion Criteria:

          -  Patients with relapsed disease post-HCT.

          -  Significant psychiatric or other co-morbid disease, which the treating clinician
             believes prohibits the patient's ability to participate in the informed consent
             procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Areej El-Jawahri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 2, 2015</study_first_submitted>
  <study_first_submitted_qc>July 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2015</study_first_posted>
  <results_first_submitted>September 29, 2019</results_first_submitted>
  <results_first_submitted_qc>November 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 27, 2019</results_first_posted>
  <last_update_submitted>November 10, 2019</last_update_submitted>
  <last_update_submitted_qc>November 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>El-Jawahri, Areej,M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Sexual Dysfunction Post-Bone Marrow Transplant</keyword>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT02492100/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Arm Pre and Post Sexual Health Intervention</title>
          <description>A total of 47 patients who screened positive for sexual dysfunction causing distress agreed to participate in this pre-/post- design single-arm study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Multi-modality Sexual Dysfunction Intervention</title>
          <description>- Patients in remission &gt; 6 months after allogeneic bone marrow transplant
Patient Enrollment and Baseline Data Collection
First Intervention Visit:
Comprehensive assessment of sexual dysfunction
Normalization &amp; Education
Therapeutic interventions
Referral to Sexual Health Clinic if applicable
Follow-Up Intervention Visit --- Referral to Sexual Health Clinic if applicable
Multi-modality sexual dysfunction intervention</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.5" lower_limit="24" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Global satisfaction with sex</title>
          <description>score ranges from 3-20 with higher scores indicating more satisfaction</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.07" spread="8.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Interest in sex</title>
          <description>raw score ranges from 2-20 with higher scores indicating more interest in sex</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.98" spread="3.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>quality of life</title>
          <description>quality of life measured by FACT-BMT with score range of 0-164 with higher score indicating better quality of life</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107.98" spread="22.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Depression (HADS)</title>
          <description>using the HADS-Depression, score range 0-21 with higher score indicating higher depression symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.28" spread="3.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anxiety (HADS)</title>
          <description>using the HADS-Anxiety score range 0-21, with higher scores indicating higher anxiety symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.59" spread="3.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Feasibility Primary Endpoint</title>
        <description>intervention deemed feasible if at least 75% of patients screening positive for sexual dysfunction causing distress agree to participate and at least 80% complete at least one additional follow-up visit. This is not a composite outcome. Study is deemed feasible (yes) if both criteria are met.</description>
        <time_frame>6 months</time_frame>
        <population>overall 94% (47 of 50) patients who screened positive for sexual dysfunction agreed to participate in the study and 80% attended at least 2 intervention visits</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Study</title>
            <description>single arm study, pre/post design</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility Primary Endpoint</title>
          <description>intervention deemed feasible if at least 75% of patients screening positive for sexual dysfunction causing distress agree to participate and at least 80% complete at least one additional follow-up visit. This is not a composite outcome. Study is deemed feasible (yes) if both criteria are met.</description>
          <population>overall 94% (47 of 50) patients who screened positive for sexual dysfunction agreed to participate in the study and 80% attended at least 2 intervention visits</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sexual Function: Promis Sexual Function and Satisfaction Measure</title>
        <description>Interest in sex at 6 months, raw score range 2-20 with higher scores indicating higher interest.</description>
        <time_frame>Baseline to 6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Singe Arm Pre/Post Design</title>
            <description>single arm pre/post design</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sexual Function: Promis Sexual Function and Satisfaction Measure</title>
          <description>Interest in sex at 6 months, raw score range 2-20 with higher scores indicating higher interest.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.39" spread="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life: Functional Assessment of Cancer Therapy- Bone Marrow Transplant</title>
        <description>quality of life at 6 months compared to baseline using the Functional Assessment of Cancer Therapy - Bone Marrow Transplant. Score range 0-164 with higher score indicating better quality of life.</description>
        <time_frame>Baseline to 6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Singe Arm Pre/Post Design</title>
            <description>single arm pre/post design</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life: Functional Assessment of Cancer Therapy- Bone Marrow Transplant</title>
          <description>quality of life at 6 months compared to baseline using the Functional Assessment of Cancer Therapy - Bone Marrow Transplant. Score range 0-164 with higher score indicating better quality of life.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.88" spread="17.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Psychological Distress Scores - Hospital and Anxiety Depression Scale and Patient Health Questionnaire-9</title>
        <description>change in HADS depression score, depression subscale of the HADS has a score range of 0-21, with higher scores indicating more depression symptoms.</description>
        <time_frame>Baseline to 6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Study</title>
            <description>single arm study, pre/post design</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Psychological Distress Scores - Hospital and Anxiety Depression Scale and Patient Health Questionnaire-9</title>
          <description>change in HADS depression score, depression subscale of the HADS has a score range of 0-21, with higher scores indicating more depression symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>no adverse events</desc>
      <group_list>
        <group group_id="E1">
          <title>Single Arm Study</title>
          <description>single arm study, pre/post design</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Areej El-Jawahri</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>248-763-3912</phone>
      <email>ael-jawahri@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

